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http://dx.doi.org/10.1016/j.jmii.2013Background: Carbapenem-resistant Acinetobacter baumannii has emerged as an important
cause of nosocomial infections with high morbidity and mortality. The carbapenemases, espe-
cially class D carbapenem-hydrolyzing oxacillinases (CHDLs), play an important role, but the
relationship between their prevalence trend and carbapenem resistance remains unclear.
Materials and methods: Between 1995 and 2012, we collected 667 isolates of A. baumannii
from a single medical center in northern Taiwan. Pulsed-field gel electrophoresis (PFGE) was
used to determine clonality. Antimicrobial susceptibility was determined. Carbapenemase
genes and associated genetic structures were detected by polymerase chain reaction.
Results: Isolates were heterogeneous on PFGE. Susceptibility to carbapenem decreased
steadily over the study period from 88.1% (2001e2003) to <25% (2010e2012), whereas the iso-
lates remained susceptible to colistin (nearly 100%) and partially susceptible to tigecyclineof Emergency Medicine, Taipei Veterans General Hospital, Number 201, Section 2, Shih-Pai Road,
m (Y.-T. Lee).
an Society of Microbiology. Published by Elsevier Taiwan LLC. All rights reserved.
.07.005
58 W.-W. Ku et al.(80%). Starting in 2001, isolates carrying the ISAba1-blaOXA-51-like allele were consistently iden-
tified. Isolates containing the transposons Tn2006 or Tn2008 first appeared in 2007 with
increasing carriage rates from 17.5% (2007e2009) to 50.0% (2010e2012). The IS1008-DISA-
ba3-blaOXA-58-like, blaOXA-72 and metallo-b-lactamase genes were detected only sporadically.
Isolates carrying CHDL genes were resistant to multiple drugs, including carbapenem, but re-
mained susceptible to colistin (100.0%).
Conclusion: Increased carbapenem resistance in A. baumannii may be caused by the increased
prevalence of isolates containing the ISAba1-blaOXA-51-like allele and the transposons Tn2006
and Tn2008.
Copyright ª 2013, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
During the past decade, Acinetobacter baumannii has
emerged as a central cause of nosocomial infections with
high morbidity and mortality.1,2 Carbapenem resistance in
this pathogen is increasing steadily worldwide.3 Studies by
the Taiwan Surveillance of Antimicrobial Resistance program
have documented an increase in carbapenem resistance
rates among A. baumannii-Acinetobacter calcoaceticus
complex (Abc) isolates from 3.4% in 2002 to 58.7% in 2010.4
Previous studies also report decreased susceptibility to
second-line antimicrobial agents such as ampicillin/sulbac-
tam, tigecycline, and colistin in carbapenem-resistant A.
baumannii (CRAB).5,6
Themost commonmechanisms of carbapenem resistance
in A. baumannii are the overexpression of intrinsic b-lacta-
mases and the acquisition of exogenous carbapenemases
such as the class D carbapenem-hydrolyzing oxacillinases
(CHDLs).3,7 These oxacillinases were first discovered in 1993
and are important enzymes that contribute to the mecha-
nism of carbapenem resistance in this species; four different
clusters of CHDLs have been identified in A. baumannii to
date.8,9 Several cross-sectional studies show that different
CHDL genes contribute differentially to antimicrobial resis-
tance in A. baumannii in Taiwan.10e13 The prevalence of
differentCHDLs inA.baumanniidictates the susceptibility to
various antimicrobial agents, but the time-course of acqui-
sition of resistance genes remains unknown.
In this study, we investigated trends in antimicrobial
resistance and correlated the trends to the acquisition of
CHDL genes in A. baumannii. Isolates obtained during an
18-year period were collected from a single large medical
center in northern Taiwan. We also determined the resis-
tance profile of isolates carrying different CHDL genes.Materials and methods
Bacterial isolates and species identification
The study was conducted at the Taipei Veterans General
Hospital, a 2900-bed tertiary care medical center in
Taiwan. Between 1995 and 2012, nonrepetitive blood iso-
lates from bacteremic patients were collected and pheno-
typically assessed by using the API ID 32 GN system
(bioMe´rieux, Marcy l’Etoile, France) or the Vitek 2 bacterialidentification system (bioMe´rieux). A. baumannii was
identified at the genomic species level by a multiplex po-
lymerase chain reaction (PCR) assay for the detection of a
specific 16S-23S rRNA intergenic spacer, as described
previously.14,15
Pulse-field gel electrophoresis
The clonality of randomly selected isolates from different
years was determined with pulsed-field gel electrophoresis
(PFGE), as previously described.16 In brief, after digestion
with ApaI, the DNA fragments were subjected to PFGE in 1%
SeaKem Gold agarose gels (Cambrex Bio Science, Rockland,
ME, USA) in 0.5 Tris/borate/ EDTA buffer (45 mM Tris,
45 mM boric acid, 1.0 mM EDTA, pH 8.0). The stained gel
was photographed and analyzed by BioNumerics software
(Applied Maths, Sint-Martens-Latem, Belgium) to generate
a dendrogram of relatedness among the isolates. Isolates
with >85% similarity were considered clonal.17
Antibiotic susceptibility testing
The minimum inhibitory concentration (MIC) for tigecycline
was determined by Etest (AB BIODISK, Solna, Sweden) and
for colistin, by agar dilution using colistin sulfate (Sigma-
Aldrich, St. Louis, MO, USA). All other MICs, including MICs
for imipenem and meropenem, were determined by broth
dilution by using the automated Sensititre Susceptibility
Plate (TREK Diagnostic Systems Ltd., East Grinstead, United
Kingdom). Results were interpreted in accordance with the
Clinical and Laboratory Standards Institute18; however, for
tigecycline the susceptibility/resistance breakpoints were
interpreted in accordance with the U.S. Food and Drug
Administration criteria (i.e., susceptible, 2 mg/L; resis-
tant, 8 mg/L).
Detection of CHDLs and transposons
A multiplex PCR assay was used to detect CHDL genes (i.e.,
blaOXA-23-like,, blaOXA-24-like, blaOXA-51-like, blaOXA-58-like, and
blaOXA-143), as previously described.
13,19,20 The upstream lo-
cations of the insertion sequences (ISs) were mapped by PCR
with forward primerswithin the ISs and reverse primerswithin
the carbapenemase genes.3,10,13,21 Metallo-b-lactamases
(MBLs) were detectedwith the imipenemand imipenem-EDTA
Carbapenem resistance in Acinetobacter baumannii 59combined-disk test, the imipenem and EDTA-sodium mercap-
toacetic acid double-disk synergy test, and PCR assays using
primers specific for theblaIMP,blaVIM,blaSIM,blaSPM, andblaGIM-
1 genes, as previously described.
22e25 To detect the trans-
posons Tn2006 and Tn2008, PCR mapping was used. The
common regions of Tn2006 and Tn2008 (923 bp from blaOXA-23
to DATPase) were amplified by using the primer P3
(Tn2006OXA23: 50-GTCTATCAGG AACTTGCGCG-30) and the
primer P5 (TN2008ATPase; 50-GGCTCATTAC AGTCAGGTAC
AAGT-30). For Tn2006, PCRwas performedwith primers P3 and
P4 (Tn2006ISAba1; 50-GCAAGGCTTT AGATGCAGAA GA-30) to
amplify the 2237-bp regionbetweenblaOXA-23-like and ISAba1 in
Tn2006.12,26
Antimicrobial use
Information regarding the defined daily dose (DDD) and
days of therapy per patient was collected. The DDD was
developed by the World Health Organization to standardize
the usage of drugs among healthcare environments. The
DDD is defined as the assumed average maintenance dose
per day for a drug used for its main indication. It is adjusted
for bed occupancy and is presented as the DDD per 1000
patient-days.27 The data on imipenem and meropenem use
have only been available since 2005.
Results
Isolates and clonality determined by PFGE
During the study period, 668 unique isolates of A. bau-
mannii were collected. We excluded one isolate from
analysis because of a lack of antimicrobial susceptibility
data. We performed PFGE on two randomly selected iso-
lates for each year in the study period to determine
whether clonal relationships existed. A heterogeneous
pattern was revealed, but without the detection of any
major pulsotype (Fig. 1).
Trends of susceptibility to different antimicrobial
agents
Fig. 2 shows the susceptibility trends of different antimi-
crobial agents between 1995 and 2012. The susceptibility to
carbapenem (e.g., imipenem and meropenem) started to
decline during the 2001e2003 period. Susceptibility
decreased steadily over the rest of the study period from
88.1% (2001e2003) to <25% (2010e2012). There were no
difference between the susceptibility rates of imipenem
and meropenem, except for the 2007e2009 period, during
which time A. baumannii was slightly less susceptible to
meropenem than to imipenem.
Tigecycline was introduced in this hospital in September
2007. Susceptibility to tigecycline remained stable at
approximately 80% until the end of the study period. A.
baumannii remained susceptible to colistin (approximately
100%) throughout the study period. Susceptibility rates to
other antimicrobial agents were low (<60%) with the
exception of amikacin, which increased gradually from
18.7% (1998e2000) to 65.2% (2010e2012).Detection of oxacillinase and metallo-b-lactamase
genes
Because of increased resistance to imipenem andmeropenem
over time, we investigated possible mechanisms. Carbapene-
mase genes, including CHDL genes (i.e., blaOXA-143, blaOXA-51-
like, blaOXA-58-like, blaOXA-24-like, and blaOXA-23-like) and MBL
genes (i.e., blaIMP, blaVIM, blaSIM, blaSPM, and blaGIM-1) were
detected by PCR mapping. Fig. 3 shows the carriage trends of
different clusters of CHDL genes. Isolates carrying the ISAba1-
blaOXA-51-like allele have been identified consistently since the
2001e2003 period. The carriage rate peaked (23.3% of all the
isolates collected) during 2004e2006. Isolates carrying trans-
posons Tn2006 and/or Tn2008 were absent until 2007, after
which a sharp increase in carriage ratewas observed (17.5% for
Tn2006 and/or Tn2008 during 2007e2009 vs. 50.0% for Tn2006
and/orTn2008during2010e2012).TheotherCHDLgenes (i.e.,
IS1008-DISAba3-blaOXA-58-like and blaOXA-72,) were detected
only sporadically. The MBL genes were detected in only seven
isolates. Six isolates contained blaVIM alone, and one isolate
harbored both blaIMP and blaVIM. Only four isolates carried the
MBL and CHDL genes. Three isolates contained the ISAba1-
blaOXA-51-like gene and one isolate carried the IS1008-DISAba3-
blaOXA-58-like gene.
Antibiotic susceptibility of A. baumannii carrying
different carbapenemase genes
We further analyzed the antibiotic susceptibility of isolates
carrying CHDL genes (Table 1). A. baumannii isolates with the
ISAba1-blaOXA-51-like allele were resistant to carbapenem and
multiple other antimicrobial agents, including aminoglyco-
sides, quinolones, ampicillin/sulbactam,andotherb-lactams.
However, they remained fully susceptible to colistin (100.0%)
and partially susceptible to tigecycline (83.3%). In the isolates
carrying the IS1008-DISAba3-blaOXA-58-like and the blaOXA-72
alleles also had multidrug-resistance patterns. Isolates with
theblaOXA-72allelewerehighly resistant toalmostevery tested
antimicrobial agent, including tigecycline; however, both
isolates remained fully susceptible to colistin (100.0%).
Isolates carrying the transposons Tn2006 and/or Tn2008
also exhibited resistance to amikacin, ciprofloxacin, levo-
floxacin, ampicillin/sulbactam, various b-lactams, and car-
bapenem. However, the susceptibility to amikacinwas slightly
higher (42.9%) in these isolates than in isolates carrying other
CHDLalleles.The isolates remainedfully susceptible tocolistin
(100.0%) and were partially susceptible to tigecycline (70.6%).
The seven A. baumannii isolates carrying the MBL genes
(four of which also harbored CHDL genes) had low suscepti-
bility to carbapenem (40.0% for imipenem and 0.0% for mer-
openem), amikacin (0.0%), ciprofloxacin (14.3%), ampicillin/
sulbactam (57.1%), piperacillin/tazobactam (40.0%), ceftazi-
dime (0.0%), and cefepime (28.6%). Only three isolates were
tested for resistance to colistin, and all three isolates were
susceptible.
Trends of carbapenem susceptibility and
antimicrobial consumption
We compared the susceptibility rates of A. baumanii to
imipenem and meropenem by using data on carbapenem
Figure 1. Pulsed-field gel electrophoresis profiles of Apa1-digested genomic DNA from randomly selected isolates of Acineto-
bacter baumannii. The numbers on the right represent the isolate number.
60 W.-W. Ku et al.use (depicted as DDD per 1000 patient-days; Fig. 4). The
steady increase of imipenem and meropenem use from
2006 (5.1 DDD/1000 patient-days for imipenem and 8.2
DDD/1000 patient-days for meropenem) to 2010 (10.1 DDD/
1000 patient-days and 10.8 DDD/1000 patient-days,
respectively) coincided with a steep decrease in the sus-
ceptibility of A. baumanii to these antimicrobial agents.
Reduced consumption of imipenem from 2010 to 2012 (8.2
DDD/1000 patient-days and 6.4 DDD/1000 patient-days in
2011 and 2012, respectively) was correlated with a slight
rebound of susceptibility to imipenem and meropenem
from 19.0% to nearly 30.0% during that period.Discussion
This 18-year longitudinal study of 667 isolates of genomic
species identified as A. baumannii revealed a continuous
increase in resistance to carbapenem. Increased resistance
may be caused by the appearance and acquisition of anti-
biotic resistance genes during this time. The ISAba1-blaOXA-
51-like gene appeared in 2001, whereas the IS1008-DISAba3-
blaOXA-58-like and blaOXA-72 genes appeared sporadically
throughout the study period. In the past 5 years, isolates
have emerged that carry the ISAba1-blaOXA-23-like gene and
the transposons Tn2006 and Tn2008.
Figure 2. Susceptibility of Acinetobacter baumannii to
antimicrobial agents from 1995 to 2012. The number of isolates
in each interval was 33 isolates (1995e1997); 116 isolates
(1998e2000); 84 isolates (2001e2003); 172 isolates (in
2004e2006); 157 isolates (2007e2009); and 105 isolates
(2010e2012). AM/S Z ampicillin/sulbactam; AN Z amikacin;
CIP Z ciprofloxacin; Colis Z colistin; FEP Z cefepime;
IPM Z imipenem; LEV Z levofloxacin; MEM Z meropenem;
PIP/TAZ Z piperacillin/tazobactam; TAZ Z ceftazidime;
TGC Z tigecycline.
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Carbapenem resistance in Acinetobacter baumannii 61The upstream insertion of ISAba1 to the intrinsic allele
blaOXA-51-like has been associated with carbapenem resis-
tance in A. baumannii.3 Our study confirmed this finding.
We determined that the emergence of these resistance-
associated genetic structures, which appeared in our
institution in 2001, correlated with the decreased suscep-
tibility of A. baumannii to carbapenem. Because of the
chromosomal location of blaOXA-51-like in A. baumannii,
ISAba1-blaOXA-51-like may persist in the genome and may be
transferred to daughter cells during reproduction, thereby
contributing to its consistent existence, compared to other
plasmid-borne CHDL genes that were detected only
sporadically. A recent nationwide study by Chuang et al28
determined that the most commonly detected carbapene-
mase gene in A. baumannii was ISAba1-blaOXA-51-like, and
the results suggested that the increase in this resistance
gene occurred because of clonal spreading.Figure 3. CHDL gene carriage in Acinetobacter baumannii
from 1995 to 2012.
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Figure 4. Susceptibility of Acinetobacter baumannii to imipenem and meropenem (curves) and carbapenem use, depicted as the
defined daily dose per 1000 patient-days (bars) from 2005 to 2012. DDD Zdefined daily dose; IPM Z imipenem;
MEM Z meropenem.
62 W.-W. Ku et al.A. baumannii strains carrying the blaOXA-23-like gene have
been discovered worldwide and are especially prevalent in
Asian-Pacific regions.29e32 A previous study by Lee et al12
revealed that CRAB, which harbors the blaOXA-23-like gene,
was clusteredmore frequently in central Taiwan in 2007 than
in other areas of the island. Starting in 2007, we observed an
interesting increase of Tn2006-bearing and Tn2008-bearing
isolates in the study hospital, which was located in northern
Taiwan. Lee et al33 also suggest that the blaOXA-23-like gene
replaced the ISAba1-blaOXA-51-like gene as the primary resis-
tancemechanism inothermedical centers innorthernTaiwan
in 2009. To our knowledge, the blaOXA-23-like gene is mobilized
by Tn2006, Tn2007, and Tn2008 and the dissemination of the
blaOXA-23-like gene is caused by transposons, rather than by
clonal spreading.12,34 We believe that the blaOXA-23-like gene
was also spread tonorthernTaiwanbya transposon-mediated
mechanism and that its dissemination between different
geographic regions was facilitated by patient transfer among
hospitals and nursing homes and between China and Taiwan.
Increased use of carbapenem in this institutionmay have also
facilitated the selection of strains of A. baumannii carrying
the carbapenem resistance genes. Previous studies from
China also demonstrated that the increased use of carbape-
nem contributed to the development of A. baumannii resis-
tance to imipenem and meropenem and to possible cross-
resistance with other b-lactams, aminoglycosides, and
fluoroquinolones.35
Treatment of multidrug resistant A. baumanii has been a
great challenge to clinicians, and inappropriate antimicro-
bial therapy has led to increased mortality.36 In other
studies, antimicrobial agents such as sulbactam, tigecy-
cline, and colistin, had variable efficacy against A. bau-
manii.5,6 In our study, most isolates were resistant to
ampicillin/sulbactam and only 80% were susceptible to
tigecycline. Lower susceptibility rates were observed in
isolates harboring CHDL genes such as blaOXA-72, Tn2006,
and Tn2008. By contrast, colistin showed a uniformly high
susceptibility in CRAB and in carbapenem-susceptibleisolates. Newer antimicrobial agents targeting oxacillinase
may be a viable choice against CRAB infection.
Our study was conducted in a single medical center in
northern Taiwan and spanned almost two decades. We
collected a large number of isolates, each having a com-
plete panel of CHDL and MBL genes. We conducted assays to
detect resistance-associated genes other than CHDLs and
metallo-b-lactamases. Other nonenzymatic mechanisms
such as changes in outer membrane protein and multidrug
efflux pump expressions may contribute to the declining
susceptibility to carbapenem.3,6 Specific experiments
should be designed to look at these factors.
In conclusion, our 18-year study, which contains a large
number of isolates revealed increasing resistance to car-
bapenem in A. baumannii. This resistance was likely caused
by the increased prevalence of the ISAba1-blaOXA-51-like
gene beginning in 2001, the sporadic appearance of the
IS1008-DISAba3-blaOXA-58-like and blaOXA-72 genes, and the
rapid emergence of isolates carrying the transposons
Tn2006 and Tn2008 in the past 5 years.
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